Resolve Therapeutics, a mid-stage biopharmaceutical company developing non-immunosuppressive therapies for inflammatory diseases, announced it will present updates on its platform and clinical programs in an upcoming talk titled “Cell-free Nucleic Acids as Drug Targets in Autoimmunity and Acute Brain Injury.”
The presentation, to be delivered by Dr. James Posada, chief executive officer of Resolve Therapeutics, is scheduled for December 4, 2025, in Hong Kong. Dr. Posada said the forum offers an opportunity to engage with leading scientists and clinicians working in the emerging field of cell-free nucleic acids. He noted that recent scientific advances continue to highlight the role of pathogenic nucleic acids in driving inflammation across several diseases with significant unmet need.
RSLV-132: Lead Clinical Candidate
RSLV-132 is a fully human, non-immunosuppressive biologic designed to break down extracellular pathogenic cell-free RNA (cfRNA).
Key features include:
- Fusion of catalytically active human RNase with an engineered IgG1 Fc domain
- A three-week serum half-life
- A safety profile supported by clinical studies
Unlike conventional immunosuppressive therapies that broadly inhibit immune activity, RSLV-132 aims to remove cfRNA, the upstream inflammatory trigger. Clinical activity has been observed in systemic lupus erythematosus (SLE) and Sjögren’s disease, and a phase 2 confirmatory trial is underway in Sjögren’s patients with moderate to severe symptoms.
RSLV-145: Dual-Action Preclinical Candidate
RSLV-145 is a fully human molecule combining active DNase and RNase enzymes fused to an optimized IgG1 Fc region. It is engineered to eliminate pathogenic extracellular nucleic acids implicated in both chronic and acute inflammatory conditions.
Ongoing preclinical development focuses on:
- Subarachnoid hemorrhage, where reducing cfRNA may limit brain injury
- Ischemic stroke, where DNase activity may help counteract neutrophil extracellular traps (NETs) that interfere with standard tPA therapy
About Resolve Therapeutics
Resolve Therapeutics develops therapies targeting cell-free nucleic acids in disease. The company’s pipeline, including RSLV-132 and RSLV-145, spans multiple acute and chronic inflammatory conditions where cfRNA, cfDNA, and NETs contribute to disease pathology.
